Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Glioblastoma 3 Sarcoma 1 Recurrence 1 Neoplasm Metastasis 1 Meningeal Neoplasms 1 Inhibition, Psychological 1 Hereditary Sensory and Autonomic Neuropathies 1 Glioma 1 Carcinoma, Non-Small-Cell Lung 1 Brain Neoplasms 1 Astrocytoma 1

Interventions

Cyclophosphamide 51 fludarabine 37 Dexamethasone 35 venetoclax 30 pembrolizumab 25 Rituximab 21 pomalidomide 18 Lenalidomide 18 Gemcitabine 17 fludarabine phosphate 15 Etoposide 14 Cytarabine 13 daratumumab 12 carfilzomib 11 Temozolomide 11 Injections 10 Cisplatin 10 Calcium Dobesilate 10 glofitamab 9 Nivolumab 9 Bortezomib 9 Azacitidine 9 selinexor 8 Vincristine 8 Immunotherapy, Adoptive 8 Carboplatin 8 obinutuzumab 7 cemiplimab 7 Drug Therapy 7 Bevacizumab 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recurrence × AZD1390 × 1 year × Clear all

NCT03970447 2026-06-03

GBM AGILE

Global Coalition for Adaptive Research

Phase 2/3 Recruiting

Glioblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡